BioSymetrics, Janssen, Sema4 use AI to predict COVID-19

By The Science Advisory Board staff writers

August 19, 2020 -- BioSymetrics, Sema4, and Janssen Pharmaceuticals will use artificial intelligence (AI) to predict the onset and severity of COVID-19 among different populations.

The companies will use BioSymetrics' Contingent-AI engine across several projects to characterize high-risk populations, measure and predict disease progression based on biological risk factors and treatment course, and identify markers for clinical phenotype and severity of disease. The goal of the collaboration is to enable a vaccine and a course of treatment against SARS-CoV-2.


Copyright © 2020 scienceboard.net
 


Email Address:

First Name:

Last Name:

Learn about ScienceBoard

Get the latest life sciences research and industry news, delivered straight to your inbox, for free.

Why subscribe?

ScienceBoard is uniquely focused on the business of research, addressing the biggest problems that the biomedical industry face. You’ll get breaking news, events coverage, and deep dives into the science that drives innovation, delivered to your inbox daily.

I have read and agree to the privacy policy and terms of service and wish to opt-in for ScienceBoard.net.